The Impact of Supplemental Macular Carotenoids in Alzheimer's Disease: A **Randomized Clinical Trial**

- Maggie Bolger^d, Robert F. Coen^e, Jessica Dennison^a, Kwadwo Owusu Akuffo^a, Niamh Owens^a, 5
- Rebecca Power^a, David Thurnham^e and Stephen Beatty^a
- ^aMacular Pigment Research Group, Department of Chemical and Life Sciences, Waterford Institute of Technology,
- Waterford, Ireland
- ^bHoward Foundation, Cambridge, UK
- ^cDowning College, University of Cambridge, Cambridge, UK 10
- ^dUniversity Hospital Waterford, Age-Related Care Unit, Waterford, Ireland 11
- ^eMercer's Institute for Successful Ageing, St. James's Hospital, Dublin, Ireland 12
- ^tNorthern Ireland, Centre for Food and Health (NICHE), University of Ulster, Coleraine, UK 13

Accepted 15 October 2014

Abstract. 14

- Background: Patients with Alzheimer's disease (AD) exhibit significantly less macular pigment (MP) and poorer vision when 15 compared to control subjects. 16
- Objective: To investigate supplementation with the macular carotenoids on MP, vision, and cognitive function in patients with 17 AD versus controls. 18
- Methods: A randomized, double-blind clinical trial with placebo and active arms. 31 AD patients and 31 age-similar control 19
- subjects were supplemented for six months with either Macushield (10 mg meso-zeaxanthin [MZ]; 10 mg lutein [L]; 2 mg 20
- zeaxanthin [Z]) or placebo (sunflower oil). MP was measured using dual-wavelength autofluorescence (Heidelberg Spectralis®). 21
- Serum L, Z, and MZ were quantified by high performance liquid chromatography. Visual function was assessed by best corrected 22 visual acuity and contrast sensitivity (CS). Cognitive function was assessed using a battery of cognition tests, including the 23
- Cambridge Neuropsychological Test Automated Battery (CANTAB)). 24
- Results: Subjects on the active supplement (for both AD and non-AD controls) exhibited statistically significant improvement 25
- in serum concentrations of L, Z, MZ, and MP (p < 0.001, for all) and also CS at 1.2 cpd (p < 0.039). Also, for subjects on the 26
- active supplement, paired samples t-tests exhibited four significant results (from five spatial frequencies tested) in the AD group, 27

and two for the non-AD group, and all indicating improvements in CS. We found no significant changes in any of the cognitive 28

- function outcome variables measured (p > 0.05, for all). 29
- Conclusion: Supplementation with the macular carotenoids (MZ, Z, and L) benefits patients with AD, in terms of clinically 30 meaningful improvements in visual function and in terms of MP augmentation. 31
- Keywords: Age-related macular degeneration, Alzheimer's disease, cognitive function, contrast sensitivity, lutein, meso-32 zeaxanthin, randomized clinical trial, visual function, zeaxanthin 33

INTRODUCTION

*Correspondence to: Professor John Nolan, Macular Pigment Research Group, Vision Research Centre, Carriganore House, Waterford Institute of Technology, West Campus, Carriganore, Waterford, Ireland. Tel.: +353 51 834074; E-mail: jmnolan@wit.ie.

We have recently reported in the Carotenoids and 35 Age-Related Dementia Study (CARDS, report 1) that 36 patients with mild to moderate AD exhibit significantly 37

34

ISSN 1387-2877/15/\$35.00 © 2015 - IOS Press and the authors. All rights reserved

This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License.

John M. Nolan^{a,*}, Ekaterina Loskutova^a, Alan Howard^{b,c}, Riona Mulcahy^d, Rachel Moran^a, Jim Stack^a,

less macular pigment (MP), poorer vision, and a
 higher occurrence of age-related macular degeneration
 (AMD; another age-related disorder), when compared
 to control subjects [1].

MP, which is made up of the dietary carotenoids 42 lutein (L), zeaxanthin (Z), and meso-zeaxanthin (MZ) 43 [2], is found exclusively at the central macula and can 44 be measured in vivo [3, 4]. Of note, the macula (the 45 central part of the retina) is part of the central ner-46 vous system, and it is this specialized part of the retina 47 that is responsible for central and detailed vision [5]. 48 We know that the macular carotenoids, via their short-49 wavelength (blue) light filtering [6] and antioxidant 50 properties [7, 8], play a protective role in AMD [9]. 51 We also know that MP is positively related to visual 52 function [10], and that enrichment of MP with nutri-53 tional supplements containing the macular carotenoids 54 improves visual function in normal subjects (i.e., sub-55 jects without retinal disease) [11] and in subjects with 56 early stages of AMD [12-15]. Indeed, the optical prop-57 erties of MP, which include its preferential absorption 58 of short-wavelength (blue) light, is likely to explain the 59 visual benefits noted in previous clinical trials [16]. 60

Of interest, we know from previous work that L and 61 Z are present in the brain, including in the cerebel-62 lum, pons, and frontal and occipital cortices [17–19], 63 and that their concentrations in the brain are positively 64 correlated with retinal concentrations of these nutrients 65 in primates [18] including humans [19]. Furthermore, 66 there is a growing body of evidence suggesting a 67 positive relationship between MP levels and cogni-68 tive function in humans [20-22] and Johnson et al. 69 have reported that supplementation with the macular 70 carotenoids impacts positively on cognitive function in 71 older women [23]. 72

Given the growing body of evidence showing that 73 oxidative stress and inflammation contribute to cogni-74 75 tive impairment [24, 25] and AD pathogenesis [26, 27], it is plausible that carotenoids in the brain could protect 76 against such stresses, given their proven antioxidant [7, 77 8] and anti-inflammatory properties [28, 29]. It has also 78 been suggested that the carotenoids may play a benefi-79 cial role by enhancing gap junctional communication 80 in the brain [30-32]. 81

In summary, we have already reported that patients 82 with AD have significantly less MP, lower serum con-83 centrations of L and Z, poorer vision, and a higher 84 occurrence of AMD when compared to control sub-85 86 jects. Also, there is a biologically plausible rationale, supported by a growing body of scientific evidence, 87 which suggests that enrichment of retinal and brain 88 nutrition with the carotenoids L, Z, and MZ will protect 89

and enhance cognitive function in humans. This study was conducted to investigate the impact of supplementation with the macular carotenoids on MP (primary outcome measure), and vision and cognitive function (secondary outcome measures) in patients with AD compared with controls of similar age, and is the first study to do so.

MATERIALS AND METHODS

Study design and subject recruitment

This clinical trial began in January 2013 (i.e., the first subject visit) and ended in September 2013 (i.e., last subject six month visit).

31 patients with mild to moderate AD (predominantly moderate) were recruited (through the Age-Related Care Unit at University Hospital Waterford [UHW]) into the study. Subjects recruited into this group (the AD group) where eligible if they had mild to moderate AD, which was defined as having an average Mini-Mental State Examination (MMSE) score of 14 to 24 with documented difficulties in other domains, such as carrying out activities of daily living, or behavioral changes. Subjects were excluded if they were currently taking supplements containing the macular carotenoids, or if they had done so over the previous 12 months. Other screening tests to check for eligibility included the clock drawing test and semantic fluency score. Co-morbid diagnoses were documented, including vascular risk factors and diabetes. Current medications were verified including cholinesterase inhibitors and glutamate receptor antagonists. Social histories were documented and collateral histories were collated from a family member or carer for all patients. Non-contrast computed tomography (CT) brain scan was performed to rule out radiological evidence of stroke disease.

Of note, 10 (32%) had also participated in the cross-sectional study previously reported by our group (CARDS1) [1] and 21 (68%) were newly recruited. Importantly, the subjects that had already participated in CARDS1 were re-examined at baseline of this study because of the time difference between the cross-sectional examination and the start of this clinical trial. Subjects with AD were randomly allocated, in a double-blind fashion to a supplement consisting of either MacushieldTM (Macuvision Europe Ltd. Blythe Valley Innovation Centre, Central Boulevard, Blythe Valley Business Park, Solihull B90 8AJ, United Kingdom) (n = 16, active supplement containing 10 mg MZ; 10 mg L; 2 mg Z) or placebo (n = 15, sunflower oil).

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

90

91

92

93

The intervention and placebo supplements were identical in external appearance and therefore the two
treatments were indistinguishable from each other.

An equal number (n=31) of age-similar controls 142 free of AD (the none-AD Group) were similarly 143 allocated to Macushield (n = 15) or Placebo (n = 16). 144 Subjects were eligible for this group if they were 145 aged (years) \geq 65. Subjects were excluded if they were 146 currently taking supplements containing the macular 147 carotenoids, or if they had done so over the previous 148 12 months. 149

Main study visits were at baseline and after six 150 months of supplementation. All measurements were 151 performed at the Vision Research Centre, Carriganore 152 House, Waterford, Ireland. This clinical trial facility 153 offers a very efficient and calm environment to con-154 duct clinical trials. For consistency, all measurements 155 were performed by the same researcher (EL) who was 156 suitably trained on all aspects and technologies for this 157 clinical trial. 158

Significant efforts were made to ensure subject com-159 pliance to the study supplements. Compliance was 160 assessed on an ongoing basis (house visits and phone 161 calls to care givers) by the study nurse (MB) for the AD 162 subjects, and by the researchers (NO and EL) for the 163 control subjects (mainly phone calls directly to the sub-164 jects). In addition, compliance was assessed by exam-165 ining pill sleeves at the six month visit and by assessing 166 serum carotenoid response using high performance liq-167 uid chromatography (HPLC, see below). The code was 168 broken at 6 months, and the statistical analysis was 169 performed by the Study Statistician (JS) and Princi-170 pal Investigator (JMN). The results of this analysis are 171 presented below. The methodology used to measure 172 MP, visual function and cognitive function has already 173 been described in detail (see CARDS report 1), so only 174 a brief account of each method is presented below. 175

176 Ethics

The project was conducted in accordance with full 177 sensitivity to the ethical requirements of the subjects 178 recruited. The study objectives and methodology com-179 plied fully with the widely recognized international 180 text and codes of practice such as the Declaration of 181 Helsinki. A protocol was developed specifically for this 182 study by the Principal Investigator (JMN) and Consul-183 tant Geriatrician (RM) at UHW to ensure that informed 184 consent was obtained appropriately, and in keeping 185 with the ethical code germane to obtaining consent 186 from vulnerable subjects (which includes patients with 187 AD). Ethical approval was granted from the local 188

Waterford South East (of Ireland) Region Ethics Committee prior to the study commencing.

Demographic, medical, ophthalmic, and lifestyle assessment

A demographic, medical, ophthalmic, and lifestyle 193 case history was obtained for each subject at baseline. 194 Body mass index (BMI) was calculated (kg/m^2) with 195 subject height (m) measured with the Leicester Height 196 Measure, and weight (kg) measured with the SECA 197 weighing scales (SECA, Birmingham, UK). Smok-198 ing status was classed as either current smoker (i.e., 199 smoked ≥ 100 cigarettes in lifetime and at least one 200 cigarette within the last 12 months) or non-smoker 201 (everybody else). Exercise was assessed by calculating 202 the total exercise for any sporting activity measured as 203 minutes per week. Diabetes was assessed by self-report 204 and also by measuring HbA1c in blood (analysis con-205 ducted offsite at Biomnis Ireland, Three Rock Road, 206 Sandyford Business Estate, Dublin 18, Ireland). 207

Cognitive function assessment

Cognition was assessed using a selection of vali-209 dated measures. The MMSE was used to measure the 210 severity of cognitive impairment. A semantic fluency 211 score was obtained using 'Animal" as the category (as 212 many exemplars as possible in one minute) and phone-213 mic fluency was measured using the 'FAS Test' (as 214 many words as possible starting with each letter, one 215 minute per letter) [33]. Also, three tasks were chosen 216 from the Cambridge Neuropsychological Test Auto-217 mated Battery (CANTAB) [34]. All were administered 218 using a finger-operated touch-screen tablet PC using 219 a set of scripted instructions. The Paired Associates 220 Learning task was selected to assess visual learning 221 and memory [35]. A modified version of the Verbal 222 Recognition Memory task was selected to assess ver-223 bal learning and memory [33]. In the modified version 224 a free recall format was used instead of a recognition 225 format. The CANTAB Motor Screening Task was used 226 to assess motor speed and accuracy by instructing the 227 subject to touch the center of a series of crosses that 228 are presented on the screen [36]. 229

Best corrected visual acuity and contrast sensitivity

The eye with best BCVA was selected as the study232eye for vision testing. If both eyes had the same BCVA,233the right one was selected. BCVA was measured with a234

3

189

190

191

192

208

230

computerized LogMAR ETDRS test chart (Test Chart 235 2000 Xpert; Thomson Software Solutions) viewed at 236 4 meters (m). The Sloan Early Treatment Diabetic 237 Retinopathy Study (ETDRS) letterset was used for this 238 test. Letter contrast sensitivity (CS) was assessed using 239 the computerized LogMAR ETDRS test chart (Test Chart 2000 Pro; Thomson Software Solutions) at five 241 different spatial frequencies (1.2, 2.4, 6.0, 9.6, 15.15 242 cpd) [37]. Both these methods have been described in 243 more detail elsewhere [10, 38, 39]. 244

245 *Retinal photograph assessment*

45 degree monoscopic color photographs, centered 246 on the macula, were taken in both eyes using a Zeiss 247 Visucam 200 (Carl Zeiss Meditec AG, Jena, Germany). 248 Retinal photographs were assessed for the presence 249 or absence of early AMD, in accordance with the 250 International Classification and Grading System for 251 Age-Related Macular Degeneration by a consultant 252 ophthalmologist (SB) with a special interest in retinal 253 disease and with a published track record in grading 254 this condition [40, 41]. In brief, the presence of soft 255 drusen and/or hypo-/hyper-pigmentary changes at the 256 macula were classed as early AMD. 257

258 Macular pigment measurement

MP was measured using the Heidelberg Spectralis® 259 HRA+OCT Multicolor (Heidelberg Engineering 260 GmbH, Heidelberg, Germany). This new technology 261 utilizes confocal scanning laser ophthalmoscopy 262 (cSLO) imaging with diode lasers and uses dual-263 wavelength autofluorescence (AF) for measuring MP 264 [4, 42]. Dual-wavelength AF in this device uses two 265 excitation wavelengths, one that is well-absorbed by 266 MP (488 nm, blue), and one that is not well absorbed 267 by the pigment (518 nm, green). Of note, the AF 268 method utilized in this study has previously been 269 compared with the customized heterochromatic flicker 270 photometry (cHFP) technique for measuring MP, and 271 the measurements recorded from these two devices 272 exhibited excellent concordance [4]. However, the 273 physical (objective) AF device was deemed more 274 appropriate for this study, because patients with 275 AD might not have been able to use the subjective 276 (non-physical) cHFP device. 277

The Heidelberg Spectralis[®] AF method provides an
image of MP across its spatial profile, but here we
report just central MP (at 0.23 degrees eccentricity)
and MP volume (calculated as MP average times the area under the curve out to 8 degrees eccentricity).

Dietary intake of carotenoids

A subject's weekly intake of carotenoid-rich foods (eggs, broccoli, corn, dark leafy vegetables) was inputted into the "L/Z screener" to give a carotenoid-based diet score. The L and Z values used in the screener were those reported by Perry et al. [43]. This method of assessing and controlling for dietary intake of carotenoids has been used with success elsewhere [12]. Values are weighted for frequency of intake of the food and for bioavailability of L and Z within these foods. A ranking score reflecting the relative intakes (representing arbitrary units) was generated and used in analysis. For the AD subject, dietary habits were confirmed by a family member or carer.

Serum carotenoid assessment

Non-fasting blood samples were collected in 9 ml vacuette tubes containing a 'Z Serum Sep Clot Activator'. The blood samples were allowed to clot at room temperature for approximately 30 min and then centrifuged at 2700 rpm for 10 min in a Gruppe GC 12 centrifuge (Desaga Sarstedt) to separate the serum from the whole blood. The resulting serum samples were stored at circa -80° C until the time of batch analysis using HPLC.

First, the serum samples were analysed for L and total Z (co-eluted Z and MZ) using a reversed-phase HPLC method (Assay 1, for details of method see publication by Nolan et al. [1]). The mixed Z fraction was automatically collected from Assay 1 using an Agilent 1260 fraction collector. The eluent was dried under a solvent concentrator (MiVac, GeneVac, Mason Technologies, Dublin, Ireland) and analyzed on Assay 2 for quantification of Z and MZ (Assay 2, for details of method see publication by Thurnham et al. [44]).

Statistics

The statistical packages IBM SPSS version 21 was used for statistical analysis. Random numbers (for the allocation of subjects to active supplement or placebo) were generated in Minitab version 16; block randomization was used. This study was very close in design to a 2^2 factorial design (two factors each at two levels: Macushield/Placebo and AD/Control) with 15 subjects per cell. Such a study has statistical power of 81% to detect a main effect of 0.75 standard deviations, and power of 70% to detect an interaction effect of the same magnitude, at the 5% level of significance [45].

Outcome variables analyzed included serum carotenoids, MP, visual function measures, and

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

cognitive function measures. Between-group differ-330 ences in these outcome variables at baseline (e.g., AD 331 versus controls) were analyzed using Independent 332 Samples *t*-tests or chi-squared tests as appropriate. 333 Differences at baseline in demographic and lifestyle 334 variables were also investigated, and controlled for in 335 subsequent analyses, as appropriate. 336

The main focus of the present study was the inves-337 tigation of change in the outcome variables over time 338 (i.e., from baseline to six months). In other words, did 339 supplementing with Macushield lead to improvements 340 in these outcome variables, relative to the Placebo, and 341 did the supplement work differently for AD and con-342 trol subjects? Both of these research questions were 343 addressed using Repeated Measures Analysis of Vari-344 ance, with supplement [Macushield versus Placebo] 345 and Group [AD yes/no] as between-subjects factors, 346 and age and diet score as covariates. These covariates 347 were included in the analyses because age and diet score 348 were significantly different between AD and controls at 349 baseline. For some cognitive scores, the assumptions 350 required for Repeated Measures Analysis of Variance 351 were violated, and in these cases we resorted to infor-352 mal comparisons of change in score between AD and 353 control subjects and between supplements. 354

In reporting findings in tables and figures, however, 355 we considered that it would be more informative to 356 report the results of paired *t*-tests, separately within 357 each Supplement/Group patient category. 358

The 5% level of significance was used through-359 out all analyses, without adjustment for multiple 360 comparisons. On standard assumptions (5% level of 361 significance, two-tailed tests), the paired t-test sub-362 group analyses reported here, with about 15 subjects 363 in each subgroup, had adequate power (82%) to 364 detect "large" effect sizes (0.8 standard deviations, on 365 Cohen's definition [46]). In general, however, it should 366 be borne in mind that this small exploratory study was 367 under-powered for the detection of smaller effect sizes 368 and for the other analyses reported. 369

RESULTS 370

Baseline 371

Table 1 below presents baseline statistics for the 372 AD and control groups. Of note, the sample and data 373 374 presented here is slightly different to our already published cross-sectional paper (CARDS1), given that the 375 sample was not precisely the same for CARDS1 and 376 CARDS2. However, the conclusions are the same. We 377 confirm that, at baseline in CARDS2, AD subjects have 378

significantly lower MP, poorer vision, poorer cognitive function, and a significantly higher prevalence of AMD, when compared to the control group.

Although we had attempted, when recruiting subjects for this study, to match the AD and control groups in terms of age, it can be seen in Table 1 that the AD group is significantly older (on average), and we therefore controlled for age in any analysis comparing outcome variables in AD and control groups. We also adjusted for diet score, the other variable which differed significantly at baseline between AD and control groups.

Dropouts

Control group

All 16 subjects on placebo completed their six month study visit, whereas there were 2 dropouts (n61 and n68) in the active (Macushield) group, resulting in 13 subjects in this arm of the study. Reasons given for dropout include: logistical difficulties (e.g., transport) and did not want to continue (willingness to participate).

AD group

12 subjects on placebo completed their six month study visit and there were 3 dropouts. Reasons for dropout include: logistical difficulties and did not want to continue (ADCD7 and ADN33); moved to nursing home and could not continue (ADN30). Also, 12 subjects in the active (Macushield) group completed their six month visit and there were 4 dropouts. Reasons for dropout include: logistical difficulties and did not want to continue (ADCD13, ADN22, ADN35, and ADN36).

Compliance

All subjects returned their capsule box and sleeves 412 at their six month assessment visit. Assessment of cap-413 sule sleeves indicated that all subjects were consuming 414 the supplements over the six-month study period. Also, 415 serum carotenoid response confirmed that subjects in 416 the active group were consuming the carotenoid inter-417 vention and that subjects in the placebo group exhibited 418 no change in their serum carotenoid concentrations. 419

Changes from baseline to six months

Serum concentrations of lutein, zeaxanthin, and	421
meso-zeaxanthin after six months of	422
supplementation	423
In the Repeated Measures Analysis of change	424

in serum L, the within-subjects Time*Supplement 425

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

Variables	AD $(n=31)$	Control $(n=31)$	Sig.
Demographic and Health			
Age (years)	80 ± 7.8	76 ± 6.6	0.031
Body mass index (Kg/m ²)	24.6 ± 5.8	26.4 ± 3.4	0.174
Exercise (total minutes of exercise per week)	174 ± 218	226 ± 16	0.304
Diet (estimated lutein and zeaxanthin intake)	16 ± 8	24 ± 14	0.008
Serum lutein (µmol/L)	0.232 ± 0.113	0.297 ± 0.179	0.104
Serum zeaxanthin (µmol/L)	0.051 ± 0.035	0.074 ± 0.042	0.03
Education (total years in education)	11 ± 4	14 ± 4	0.003
Smoking (% current)	8.60%	9.70%	0.88
Gender (% female)	58%	42%	0.203
Vision			
MP 0.23	0.41 ± 0.21	0.57 ± 0.17	0.002
MP vol	4074 ± 2585	6326 ± 2258	0.001
BCVA	88.9 ± 11.4	95.8 ± 8.4	0.009
CS1.2 (cpd)	1.49 ± 0.23	$1.75 \pm .22$	< 0.001
CS2.4 (cpd)	1.47 ± 0.25	1.79 ± 0.21	< 0.001
CS6.0 (cpd)	1.19 ± 0.31	1.42 ± 0.24	0.004
CS9.6 (cpd)	0.94 ± 0.30	1.18 ± 0.26	0.005
AMD (% with AMD)	48.00%	16.00%	0.007
Cognition			
MMSE	19 ± 3.7	29 ± 1.7	< 0.001
Semantic fluency score	6.0 ± 3.2	15.4 ± 5.2	< 0.001
Phonemic fluency score	15.7 ± 10.3	32.5 ± 13.8	< 0.001
VRM (phase 1)	1.4 ± 1.2	5.1 ± 2.6	< 0.001
VRM (phase 2)	2.5 ± 1.6	7.3 ± 2.7	< 0.001
VRM (phase 3)	3.4 ± 2.1	8.1 ± 2.9	< 0.001
VRM Delayed Recall	0.4 ± 1.2	6.6 ± 3.3	< 0.001
VRM Savings Score	0.1 ± 0.2	0.8 ± 0.5	< 0.001
PAL (total errors adjusted)	136 ± 14.5	69 ± 39	< 0.001
PAL (total errors adjusted 6 shapes)	28.5 ± 5.8	17.7 ± 10.7	< 0.001
PAL Stages Complete	0.5 ± 0.9	4 ± 1.7	< 0.001
PAL Patterns Reached	2.5 ± 0.9	7.2 ± 4.9	< 0.001
PAL First Trial Memory Score	0.8 ± 2.3	9.7 ± 5.5	< 0.001

Table 1 Demographic, lifestyle, vision, and cognition data of the AD and control subjects at baseline

Data displayed are mean \pm standard deviation for interval data and percentages for categorical data. Variables, variables analyzed in the study; AD, subjects recruited into the study confirmed as having mild to moderate Alzheimer's disease; Control, subjects free of mild to moderate AD and of similar age to the AD subjects; Sig., the statistical difference (p value) between AD and control subjects assessed using independent samples t-tests or chi-squared depending on the variable of interest; Exercise, total exercise for any sporting activity measured as minutes per week; Diet, estimate of dietary intake of L and Z; Serum lutein, serum concentrations of lutein in µmol/; Serum zeaxanthin, serum concentrations of zeaxanthin in μ mol/L; Smoking, current (smoked \geq 100 cigarettes in lifetime and at least one cigarette within the last 12 months) or nonsmoking (smoked <100 cigarettes in lifetime and none within the last 12 months); MP 0.23, central macular pigment measured at 0.23 degrees eccentricity measured using the Heidelberg Spectralis[®]. MP vol, a volume of MP calculated as MP average times the area under the curve out to 8 degrees eccentricity (measured using the Heidelberg Spectralis®); BCVA, best corrected visual acuity; CS 1.2, CS 2.4, CS 6.0, and CS 9.6=letter contrast sensitivity measured using the Thomson Software Solutions at 1.2, 2.4, 6.0, and 9.6 cycles per degree; AMD; age-related macular degeneration; MMSE, Mini-Mental State Examination; Semantic fluency score, a semantic fluency (categorical verbal fluency) score obtained from the number of animals named by the subject in 1 minute; Phonemic fluency score, a phonemic fluency (word fluency) score generated by the total number of words produced for the each of the letters F, A, and S, in 1 minute. MOT (mean latency), motor screening task measures the subject's speed of response; MOT (mean error), motor screening task measures the accuracy of the subject's pointing at cross targets; VRM (phase 1), VRM (phase 2), VRM (phase 3), Verbal Free Recall Memory immediate, three consecutive trials; VRM Delayed Recall, Verbal Free Recall Memory of the previous words after a delay period; VRM Savings Score, Delayed verbal recall divided by phase 3 immediate recall; PAL, Paired Associates Learning test which measure visual memory and new learning of the subjects; PAL (total errors adjusted), the adjusted score and includes an adjustment made for any stages not reached, allowing it to be comparable to all subjects even if the task was ended prematurely due to cognitive limitation; PAL (total errors adjusted 6 shapes), total errors made at the 6-pattern stage, adjusted for subjects who did not reach this stage; PAL Stages Complete, The number of stages successfully completed; PAL Patterns Reached, The number of patterns on the last problem in the task that the subject completed successfully; PAL First Trial Memory Score, The number of patterns correctly located after the first trial, summed across the stages completed.

126	interaction effect was significant ($p < 0.001$). Ne
427	ther the Time*Group interaction $(p=0.65)$ nor the

Time*Supplement*Group interaction (p=0.97) was

significant. Thus, there was a significant increase in serum L concentrations after 6 months for subjects on the active (Macushield) supplement compared with

subjects on the placebo supplement, no significant dif-432 ference over time between AD and controls, and no 433 evidence that the supplement worked differently over 434 time for AD versus controls. 435

Similar results were obtained for serum concentra-436 tions of Z, in that the Time*Supplement effect was 437 significant (p = 0.007), but not the others; and for MZ 438 (p < 0.001 for Time*Supplement interaction). Thus, in 439 short, we report that the active supplement significantly 440 increases serum concentrations of L, Z and MZ, and it does so for both AD and control subjects. 442

441

443

444

445

446

447

448

449

450

451

452

These findings are presented in Table 2 and Fig. 1. In Table 2, all subjects on the active supplement (Macushield) exhibit significantly increased serum concentrations of L, Z, and MZ, in both control and AD subjects at six months.

The placebo categories exhibit no significant change over this time period, with the exception of a statistically significant increase in serum concentrations of L in the AD group. Although this increase observed in the placebo group, for subjects with AD, was statistically significant, it was small (only 17%) compared to the large increase (291%) observed in the active (Macushield) group for subjects with AD.

Macular pigment at baseline and after six months of supplementation

In the Repeated Measures Analysis of 458 0.23^{0} eccentricity), MP change in (at the 459 within-subjects Time*Supplement inter-460 action effect was significant (p < 0.001).461 Neither the Time*Group interaction (p=0.92) nor 462 the Time*Supplement*Group interaction (p=0.39)463 was significant. Thus, there was a significant increase 464 in central MP after 6 months, for subjects on the 465 active supplement compared with subjects on the 466 placebo supplement, no significant difference over 467 time between AD and controls, and no evidence that 468 the supplement worked differently over time for AD 469 and controls. 470

Table 2

Serum concentrations of lutein and zeaxanthin at baseline and following six months of supplementation with either active or placebo intervention

Group	Intervention	Measurement	Mean \pm SD at baseline	Mean \pm SD at six months	% Change	Sig.
Control	placebo	serum L (µmol/L)	0.319 ± 0.188	0.280 ± 0.118	-12	0.381
Control	active	serum L (µmol/L)	0.288 ± 0.177	1.05 ± 0.361	+265	p < 0.001
AD	placebo	serum L (µmol/L)	0.174 ± 0.057	0.203 ± 0.074	+17	0.035
AD	active	serum L (µmol/L)	0.261 ± 0.142	1.02 ± 0.655	+291	p < 0.001
Control	placebo	serum Z (µmol/L)	0.082 ± 0.047	0.07 ± 0.030	-15	0.321
Control	active	serum Z (µmol/L)	0.068 ± 0.036	0.126 ± 0.04	+85	0.003
AD	placebo	serum Z (µmol/L)	0.042 ± 0.024	0.062 ± 0.035	+48	0.145
AD	active	serum Z (µmol/L)	0.048 ± 0.035	0.109 ± 0.076	+127	0.02
Control	placebo	serum MZ (µmol/L)	0	0	-	_
Control	active	serum MZ (µmol/L)	0	0.082 ± 0.059	-	0.001
AD	placebo	serum MZ (µmol/L)	0	0	_	_
AD	active	serum MZ (µmol/L)	0	0.081 ± 0.089	-	0.009

Data displayed are mean ± standard deviation. % change, the calculated percentage change from baseline to six months, calculated as baseline value minus the six month value divided by baseline value, multiplied by 100 (- = negative change and + = positive change); Sig., the p value for paired-sample t testing between baseline and six months for each group split by intervention; AD, Alzheimer's disease; Active, MacushieldTM: 10 mg lutein, 10 mg meso-zeaxanthin, and 2 mg zeaxanthin; Placebo, sunflower oil.




Fig. 1. Serum concentrations of lutein, zeaxanthin, and meso-zeaxanthin at baseline and six months by group and intervention. 0, baseline; 6, six months; C, control group; A, Alzheimer's group; P, placebo supplement; A, active supplement.

453

454

455

456

471	Similar results were obtained for MP volume, in
472	that only the Time*Supplement effect is significant
473	(p < 0.001). Thus, in short, we report that the supple-
474	ment works to increase MP, both centrally and across

the spatial profile, and it does so for both AD and non-AD (control) subjects.

These findings are presented in Table 3 and Fig. 2. In Table 3, all subjects on the active supplement

Macular pigment at baseline and following six months of supplementation with either active or placebo intervention						
Group	Intervention	Measurement	Mean \pm SD at baseline	Mean \pm SD at six months	% Change	Sig.
Control	placebo	MP at 0.23°	0.58 ± 0.18	0.54 ± 0.18	-7	0.300
Control	active	MP at 0.23°	0.58 ± 0.18	0.68 ± 0.19	+17	0.002
AD	placebo	MP at 0.23°	0.40 ± 0.17	0.38 ± 0.18	-5	0.86
AD	active	MP at 0.23°	0.41 ± 0.26	0.48 ± 0.19	+17	0.009
Control	placebo	MP volume	6543 ± 2150	6473 ± 2131	-1	0.394
Control	active	MP volume	6593 ± 2116	8291 ± 2692	+26	p < 0.001
AD	placebo	MP volume	4008 ± 2084	4327 ± 1948	+7	0.304
AD	active	MP volume	3804 ± 2255	5408 ± 3130	+42	0.001

Table 3

Data displayed are mean \pm standard deviation. % change, the calculated percentage change from baseline to six months, calculated as baseline value minus the six month value divided by baseline value, multiplied by 100 (-=negative change and +=positive change); Sig., the *p* value for paired-sample *t* testing between baseline and six months for each group split by intervention; MP at 0.23°, macular pigment at 0.23 degrees eccentricity; MP volume, MP average times the area under the curve out to 8 degrees eccentricity; AD, Alzheimer's disease; active, MacushieldTM: 10 mg lutein, 10 mg meso-zeaxanthin, and 2 mg zeaxanthin; placebo, sunflower oil.




Fig. 2. Mean macular pigment at baseline and after six months of supplementation with either active supplement (Macushield) or placebo in subjects with Alzheimer's disease and control subjects.

475 476

(Macushield) exhibit significantly increased MP, in
both non-AD (control) and AD subjects, at six months.
The placebo subjects exhibit no significant change over

482 this time period.

Visual function at baseline and after six months ofsupplementation

485 Best corrected visual acuity

Repeated Measures Analysis of change in BCVA 486 produced just one statistically significant effect, the 487 Time*Supplement interaction effect (p = 0.005). Fur-488 ther examination shows that this effect arises because, 489 unexpectedly, in both AD subjects and controls, aver-490 age BCVA increased slightly with time in the placebo 491 subjects, but declined in the Macushield subjects. Of 492 note, however, the change observed here, although sta-493 tistically significant, does not represent a meaningful 494 change (clinically) in BCVA. Moreover, the paired 495 samples t-test produced no significant results for either 496 group, regardless of supplement (p > 0.05, for all). 497

498 Contrast sensitivity

Contrast

In the Repeated Measures Analysis of change in CS at 1.2 cpd, the within-subjects Time*Supplement interaction effect was significant (p < 0.039). Neither the Time*Group interaction (p = 0.23) nor the Time*Supplement*Group interaction (p = 0.90) was significant. Thus, there was a significant increase in CS at 1.2 cpd after 6 months for subjects on the active supplement compared with subjects on the placebo supplement, no significant difference over time between AD and non-AD (control) subjects, and no evidence that the supplement worked differently over time for AD and non-AD (control) subjects.

No statistically significant findings were observed,
from the Repeated Measures analysis, for CS at other fre-
quencies. Examining the paired *t*-test results in Table 4
and Fig. 3, however, subjects on the active supple-
ment exhibited four significant results (from five spatial
frequencies tested) in the AD group, and two for the non-
AD group, and all indicating improvements in CS.511

Cognitive function at baseline and after six months of supplementation

We found no statistically significant main or interac-520 tion effects (p > 0.05, for all variables analyzed) from 521 the Repeated Measures Analysis of any of the cognitive 522 function outcome variables measured (see Table 1 for 523 list of variables analyzed). Thus, supplementation with 524 Macushield, over the six months of the study, did not 525 significantly improve any of these cognitive function 526 scores, in either AD or non-AD (control) subjects. 527

DISCUSSION

This report (CARDS 2) presents findings from a six-month macular carotenoid interventional, double-

Table 4
t sensitivity at baseline and following six months of supplementation with either active or placebo intervention

Group	Intervention	Measurement	mean \pm SD at baseline	mean \pm SD at 6 months	% Change	Sig.
Control	placebo	CS at 1.2cpd	1.83 ± 0.154	1.82 ± 0.150	-0.01	0.84
Control	active	CS at 1.2cpd	1.76 ± 0.254	1.88 ± 0.249	4.9	0.006
AD	placebo	CS at 1.2cpd	1.51 ± 0.273	1.55 ± 0.320	2.9	0.108
AD	active	CS at 1.2cpd	1.47 ± 0.254	1.63 ± 0.237	11	0.04
Control	placebo	CS at 2.4cpd	1.81 ± 0.180	1.83 ± 0.185	1.1	0.6
Control	active	CS at 2.4cpd	1.73 ± 0.350	1.82 ± 0.290	5	0.038
AD	placebo	CS at 2.4cpd	1.47 ± 0.420	1.48 ± 0.402	0.7	0.461
AD	active	CS at 2.4cpd	1.48 ± 0.226	1.55 ± 0.241	4.9	0.048
Control	placebo	CS at 6.0cpd	1.37 ± 0.240	1.46 ± 0.205	3.3	0.275
Control	active	CS at 6.0cpd	1.57 ± 0.196	1.59 ± 0.161	0.3	0.687
AD	placebo	CS at 6.0cpd	1.34 ± 0.263	1.34 ± 0.309	0	0.785
AD	active	CS at 6.0cpd	1.17 ± 0.255	1.29 ± 0.303	10	0.16
Control	placebo	CS at 9.6cpd	1.16 ± 0.286	1.16 ± 0.350	0	0.919
Control	active	CS at 9.6cpd	1.27 ± 0.222	1.32 ± 0.171	4	0.38
AD	placebo	CS at 9.6cpd	1.03 ± 0.266	1.04 ± 0.300	0.9	0.84
AD	active	CS at 9.6cpd	0.87 ± 0.308	1.00 ± 0.340	16	0.011
Control	placebo	CS at 15.15cpd	0.89 ± 0.31	0.83 ± 0.32	-7	0.39
Control	active	CS at 15.15cpd	0.75 ± 0.36	0.88 ± 0.25	16	1.76
AD	placebo	CS at 15.15cpd	0.85 ± 0.16	0.79 ± 0.16	-7	0.471
AD	active	CS at 15.15cpd	0.68 ± 0.24	0.85 ± 0.24	25	0.047

Data displayed are mean \pm standard deviation. Sig., the *p* value for paired-sample *t* testing between baseline and six months for each group split by intervention; CS, contrast sensitivity; cpd, cycles per degree; AD, Alzheimer's disease; active, MacushieldTM: 10 mg lutein, 10 mg meso-zeaxanthin, and 2 mg zeaxanthin; placebo, sunflower oil.

505

506

507

508

509

510

518

519

528

529




Fig. 3. Contrast sensitivity curve at baseline and after six months of supplementation with either active supplement (Macushield) or placebo in subjects with Alzheimer's disease and control subjects.

blind, placebo-controlled, randomized, clinical trial, in 531 subjects with mild to moderate AD (AD subjects) com-532 pared with controls of similar age (control subjects). 533 The rationale for conducting this experiment follows on from the previously reported finding that patients 535 with moderate AD have significantly lower MP, and 536 significantly poorer visual function, when compared to 537 control subjects of similar age. Also, given that enrich-538 ment of MP has been shown to improve visual function, 539 in both diseased [12] and non-diseased retinae [11], it 540 was logical to investigate whether a similar effect could 541 be achieved in patients with AD, where baseline visual function was sub-optimal. Of note, this is the first study 543 of its kind to attempt to answer this important research 544 question. 545

It is known that patients with dementia and AD have 546 poor diets lacking in fruit and vegetables [47-49] and 547 therefore we know that, on average, patients with AD 548 consume less carotenoids than patients free of AD. 540 Furthermore, it has been shown that high serum con-550 centrations of L+Z are associated with a lower risk of 551 AD mortality in adults [50] and that plasma antioxi-552 dants are depleted in mild cognitive impairment and in 553 AD when compared to subjects with normal cognitive 554 function [51]. Indeed, our data is consistent with the 555 above studies, as we confirm that (at baseline) patients 556 with AD have significantly lower (33% lower) dietary 557

intake of foods known to contain the carotenoids (L and Z) when compared to control subjects of comparable age. Also, we found that serum concentrations of L and Z were significantly lower in subjects with AD when compared to control subjects (21% lower for L and 31% lower for Z). These findings in diet and serum were reflected in the MP data, with AD subjects exhibiting significantly lower MP (28% lower on average) when compared to control subjects. Finally, our data also confirms findings from our earlier publication [1], in that subjects with AD have significantly poorer vision when compared to the control subjects (e.g., for CS at 2.4 cpd, subjects with AD have lower CS [17.9%] when compared to controls).

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

The main findings from our study are that AD sufferers who were supplemented with a carotenoid formulation containing 10 mg MZ, 10 mg L, and 2 mg of Z, exhibited significant increases in serum concentrations of MZ, L, and Z, and in MP, with consequential improvements in visual function (in terms of CS); whereas, the placebo groups exhibited no significant change in any of these outcome measures. Of note, the increases observed in MP (and serum concentrations of its constituent carotenoids) were comparable between AD and non-AD (control) subjects. Indeed, at six months, subjects receiving the active intervention (10 mg MZ, 10 mg L, and 2 mg Z) were comparable

in terms of average circulating serum concentrations 585 of L, Z, and MZ, irrespective of whether they were in 586 the AD or non-AD (control) groups, with no signif-587 icant difference between these groups for any of the 588 carotenoids at this point (p > 0.05 for all comparisons). 589 The importance of this finding rests on the logical 590 conclusion that the observed and relative lack of circu-591 lating serum carotenoid concentrations and MP in AD 592 [1] is not attributable to an inability of these patients to 593 respond to carotenoid intake (e.g., they are not compro-594 mised in terms of carotenoid absorption, transport, or 595 uptake). In other words, the findings are consistent with 596 the view that the reason why patients with AD have 597 lower MP compared to control subjects is likely due to 598 an associated poor dietary intake of foods containing 599 carotenoids (fruits and vegetables). 600

With respect to the serum and MP response exhib-601 ited in both AD and non-AD (control) groups, our data 602 is consistent with previous studies where a supple-603 ment containing all three of the macular carotenoids 604 (10 mgMZ, 10 mgL, and 2 mgZ) was used [11, 12, 605 52, 53]. Indeed, it is noteworthy from previous studies 606 that carotenoid supplements that do not contain MZ 607 in their formulation did not augment MP significantly 608 at six months [38, 54]. It appears, therefore, that best 609 results in terms of increasing serum carotenoid concen-610 trations (for MZ, L, and Z), and MP augmentation, is 611 achieved when all three of the macular carotenoids are 612 included in the formulation, and this observation also 613 holds true for patients with AD. Further, supplementa-614 tion with macular carotenoids, and consequential MP 615 augmentation, is associated with risk reduction for 616 AMD, a particularly important benefit as intervention 617 with current treatment modalities (i.e., monthly injec-618 tions, under local anesthesia, into the eye) would be 619 problematic in this patient group. 620

We believe that it is important to draw attention to 621 622 our findings pertaining to visual function. Firstly, we confirm that CS is significantly lower in AD subjects 623 when compared to non-AD controls. Addressing this 624 sensory defect in vulnerable AD patients should be 625 a priority for those involved in the care of patients 626 with this form of cognitive impairment, and routine 627 and frequent assessment of visual function should be 628 incorporated into the delivery of that care. For example, 629 improvements seen among AD subjects supplemented 630 with MZ, L, and Z were clinically meaningful at 631 spatial frequencies of 1.2 cpd and 15.15 cpd, equat-632 ing to approximately one line of improvement on 633 standard Pelli-Robson chart, and likely to enhance 634 visual appreciation of small and large targets by these 635 subjects. We suggest that further studies may con-636

sider other measures of visual function (e.g., glare disability and photostress recovery), however, the feasibility of including these measures will need to be considered given the time required to perform the tests and the ability of the subject to perform each test.

Of note, no improvements in cognitive function were 643 demonstrated as a result of supplementation in either 644 AD or non-AD control subjects, a finding that is neither 645 surprising nor counter-intuitive. The rationale whereby 646 antioxidants are important for cognition rests on their 647 ability to prevent or attenuate oxidative damage, as 648 opposed to tissue repair. In other words, there is a 649 biologically plausible rationale, supported by emerg-650 ing evidence, that antioxidant intake is protective for 651 cognition, but the notion that established cognitive 652 impairment could be reversed by supplementation with 653 antioxidants is less probable, especially in the context 654 of a short period of intervention (as reported herein). 655 Therefore, to investigate properly if supplementation 656 with the carotenoids L, Z, and MZ impact positively 657 on cognitive health/function, we suggest that subjects 658 with very early signs of cognitive decline, and subjects 659 of comparable age with no signs of cognitive decline 660 are selected, and are followed for at least 3 years. The 661 current study confirms that AD patients respond to 662 carotenoid supplements in the same way as normal 663 controls, and therefore it is possible that supplemen-664 tation with these nutrients, if achieved early enough, 665 may support and protect cognitive health. 666

In conclusion, our data suggests that supplementa-667 tion with the macular carotenoids (MZ, Z, and L) may 668 benefit patients with AD, in terms of clinically mean-669 ingful improvements in visual function and in terms 670 of MP augmentation (and consequential risk reduction 671 for AMD). The impact of sustained supplementation 672 on cognition and visual function in AD subjects, and 673 on risk for AD, both warrant further study. 674

ACKNOWLEDGMENTS

We would like to thank the Howard Foundation, Cambridge, CB22 5LA, United Kingdom for supporting this research. We would like to acknowledge Cambridge Cognition, UK for guidance with respect to the assessment of cognitive function. Also, we would like to thank all the staff at the UHW, Age-Related Care Unit and at the Vision Research Centre, Waterford Institute of Technology for assisting this study.

Authors' disclosures available online (http://www.jalz.com/disclosures/view.php?id=2602). 637

638

639

640

641

642

675

676

677

678

679

680

681

682

683

REFERENCES 685

- Nolan JM, Loskutova E, Howard AN, Moran R, Mulcahy 686 [1] R, Stack J, Bolger M, Dennison J, Akuffo KO, Owens N, Thurnham DI, Beatty S (2014) Macular pigment, visual func-688 tion, and macular disease among subjects with Alzheimer's 689 disease: An exploratory study. J Alzheimers Dis 42, 1191-1202.
 - [2] Bone RA, Landrum JT, Fernandez L, Tarsis SL (1988) Analysis of the macular pigment by HPLC: Retinal distribution and age study. Invest Ophthalmol Vis Sci 29, 843-849.
 - [3] Wooten BR, Hammond BR, Land RI, Snodderly DM (1999) A practical method for measuring macular pigment optical density. Invest Ophthalmol Vis Sci 40, 2481-2489.
 - [4] Dennison JL, Stack J, Beatty S, Nolan JM (2013) Concordance of macular pigment measurements obtained using customized heterochromatic flicker photometry. dual-wavelength autofluorescence, and single-wavelength reflectance. Exp Eye Res 116, 190-198.
 - [5] Hirsch J, Curcio CA (1989) The spatial resolution capacity of human foveal retina. Vision Res 29, 1095-1101.
 - Snodderly DM, Brown PK, Delori FC, Auran JD (1984) The [6] macular pigment. I. absorbance spectra, localization, and discrimination from other yellow pigments in primate retinas. Invest Ophthalmol Vis Sci 25, 660-673.
 - [7] Khachik F, Bernstein PS, Garland DL (1997) Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Invest Ophthalmol Vis Sci 38, 1802-1811.
 - [8] Li B, Ahmed F, Bernstein PS (2010) Studies on the singlet oxygen scavenging mechanism of human macular pigment. Arch Biochem Biophys 504, 56-60.
 - Chew EY, Clemons TE, SanGiovanni JP, Danis RP, Ferris FL [9] III, Elman MJ, Antoszyk AN, Ruby AJ, Orth D, Bressler SB, Fish GE, Hubbard GB, Klein ML, Chandra SR, Blodi BA, Domalpally A, Friberg T, Wong WT, Rosenfeld PJ, Agron E, Toth CA, Bernstein PS, Sperduto RD (2013) Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol 132, 142-149.
 - Loughman J, Akkali MC, Beatty S, Scanlon G, Davison PA, [10] O'Dwyer V, Cantwell T, Major P, Stack J, Nolan JM (2010) The relationship between macular pigment and visual performance. Vision Res 50, 1249-1256.
 - [11] Loughman J, Nolan JM, Howard AN, Connolly E, Meagher K, Beatty S (2012) The impact of macular pigment augmentation on visual performance using different carotenoid formulations. Invest Ophthalmol Vis Sci 53, 7871-7880.
 - [12] Sabour-Pickett S, Beatty S, Connolly E, Loughman J, Stack J, Howard A, Klein R, Klein BE, Meuer SM, Myers CE, Akuffo KO, Nolan JM (2014) Supplementation with three different macular carotenoid formulations in patients with early agerelated macular degeneration. Retina 34, 1757-1766.
 - [13] Huang YM, Yan SF, Ma L, Zou ZY, Xu XR, Dou HL, Lin XM (2013) Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition 29, 387-392.
- Murray IJ, Makridaki M, van der Veen RL, Carden D, Parry [14] 742 743 NR, Berendschot TT (2013) Lutein supplementation over a one-year period in early AMD might have a mild beneficial 744 effect on visual acuity: The CLEAR study. Invest Ophthalmol 745 Vis Sci 54, 1781-1788. 746
- 747 [15] Weigert G, Kaya S, Pemp B, Sacu S, Lasta M, Werkmeister RM, Dragostinoff N, Simader C, Garhofer G, 748

Schmidt-Erfurth U, Schmetterer L (2011) Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 52, 8174-8178.

- [16] Wooten BR, Hammond BR (2002) Macular pigment: Influences on visual acuity and visibility. Prog Retin Eye Res 21, 225-240.
- [17] Craft NE, Haitema TB, Garnett KM, Fitch KA, Dorey CK (2004) Carotenoid, tocopherol, and retinol concentrations in elderly human brain. J Nutr Health Aging 8, 156-162.
- Vishwanathan R, Neuringer M, Snodderly DM, Schalch W, [18] Johnson EJ (2013) Macular lutein and zeaxanthin are related to brain lutein and zeaxanthin in primates. Nutr Neurosci 16, 21 - 29
- [19] Johnson EJ, Vishwanathan R, Johnson MA, Hausman DB, Davey A, Scott TM, Green RC, Miller LS, Gearing M, Woodard J, Nelson PT, Chung HY, Schalch W, Wittwer J, Poon LW (2013) Relationship between serum and brain carotenoids, alpha-tocopherol, and retinol concentrations and cognitive performance in the oldest old from the Georgia Centenarian Study. J Aging Res 2013, 951786.
- [20] Vishwanathan R, Iannaccone A, Scott TM, Kritchevsky SB, Jennings BJ, Carboni G, Forma G, Satterfield S, Harris T, Johnson KC, Schalch W, Renzi LM, Rosano C, Johnson EJ (2014) Macular pigment optical density is related to cognitive function in older people. Age Ageing 43, 271-275.
- [21] Renzi LM, Dengler MJ, Puente A, Miller LS, Hammond BR Jr (2014) Relationships between macular pigment optical density and cognitive function in unimpaired and mildly cognitively impaired older adults. Neurobiol Aging 35, 1695-1699
- [22] Feeney J, Finucane C, Savva GM, Cronin H, Beatty S, Nolan JM, Kenny RA (2013) Low macular pigment optical density is associated with lower cognitive performance in a large, population-based sample of older adults. Neurobiol Aging 34, 2449-2456.
- [23] Johnson EJ, McDonald K, Caldarella SM, Chung HY, Troen AM, Snodderly DM (2008) Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. Nutr Neurosci 11, 75-83
- Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, But-[24] terfield DA, Markesbery WR (2005) Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64, 1152-1156.
- [25] Teunissen CE, van Boxtel MP, Bosma H, Bosmans E, Delanghe J, De BC, Wauters A, Maes M, Jolles J, Steinbusch HW, de Vente J (2003) Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol 134, 142-150.
- [26] Pappolla MA, Smith MA, Bryant-Thomas T, Bazan N, Petanceska S, Perry G, Thal LJ, Sano M, Refolo LM (2002) Cholesterol, oxidative stress, and Alzheimer's disease: Expanding the horizons of pathogenesis. Free Radic Biol Med 33. 173-181.
- [27] Wyss-Coray T (2006) Inflammation in Alzheimer disease: Driving force, bystander or beneficial response? Nat Med 12, 1005-1015.
- [28] Ciccone MM, Cortese F, Gesualdo M, Carbonara S, Zito A, Ricci G, De Pascalis F, Scicchitano P, Riccioni G (2013) Dietary intake of carotenoids and their antioxidant and antiinflammatory effects in cardiovascular care. Mediators Inflam 2013. 782137.
- Kijlstra A, Tian Y, Kelly ER, Berendschot TT (2012) Lutein: [29] More than just a filter for blue light. Prog Retin Eye Res 31, 303-315.

812

813

749

750

12

687

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

- [30] Johnson EJ (2012) A possible role for lutein and zeaxanthin
 in cognitive function in the elderly. *Am J Clin Nutr* 96, 1161S 1165S.
 - [31] Stahl W, Sies H (2001) Effects of carotenoids and retinoids on gap junctional communication. *Biofactors* 15, 95-98.

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

- [32] Stahl W, Nicolai S, Briviba K, Hanusch M, Broszeit G, Peters M, Martin HD, Sies H (1997) Biological activities of natural and synthetic carotenoids: Induction of gap junctional communication and singlet oxygen quenching. *Carcinogenesis* 18, 89-92.
- [33] Strauss E, Scherman EMS, Spreen O (2006) A Compendium of Neuropsychological Tests. Administration, Norms and Commentary, Oxford University Press; New York.
- [34] Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P (1994) Cambridge Neuropsychological Test Automated Battery (CANTAB): A factor analytic study of a large sample of normal elderly volunteers. *Dementia* 5, 266-281.
- [35] Sahakian BJ, Morris RG, Evenden JL, Heald A, Levy R, Philpot M, Robbins TW (1988) A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. *Brain* 111(Pt 3), 695-718.
- [36] Owen AM, Downes JJ, Sahakian BJ, Polkey CE, Robbins TW (1990) Planning and spatial working memory following frontal lobe lesions in man. *Neuropsychologia* 28, 1021-1034.
- [37] Charalampidou S, Nolan J, Loughman J, Stack J, Higgins G, Cassidy L, Beatty S (2011) Psychophysical impact and optical and morphological characteristics of symptomatic non-advanced cataract. *Eye (Lond)* 25, 1147-1154.
- [38] Nolan JM, Loughman J, Akkali MC, Stack J, Scanlon G, Davison P, Beatty S (2011) The impact of macular pigment augmentation on visual performance in normal subjects: COMPASS. *Vision Res* **51**, 459-469.
- [39] Akuffo KO, Beatty S, Stack J, Dennison J, O'Regan S, Meagher KA, Peto T, Nolan J (2014) Central Retinal Enrichment Supplementation Trials (CREST): Design and methodology of the CREST randomized controlled trials. *Ophthalmic Epidemiol* 21, 111-123.
- [40] Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis DM, de Jong PT, Klaver CC, Klein BE, Klein R, et al. (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. *Surv Ophthalmol* **39**, 367-374.
- [41] Neelam K, Muldrew A, Hogg R, Stack J, Chakravarthy U, Beatty S (2009) Grading of age-related maculopathy: Slitlamp biomicroscopy versus an accredited grading center. *Retina* 29, 192-198.

- [42] Delori FC (2004) Autofluorescence method to measure macular pigment optical densities fluorometry and autofluorescence imaging. *Arch Biochem Biophys* **430**, 156-162.
- [43] Perry A, Rasmussen H, Johnson EJ (2009) Xanthophyll (lutein, zeaxanthin) content in fruits, vegetables and corn and egg products. *J Food Compost Anal* 22, 9-15.
- [44] Thurnham DI, Tremel A, Howard AN (2008) A supplementation study in human subjects with a combination of meso-zeaxanthin, (3R,3'R)-zeaxanthin and (3R,3'R,6'R)lutein. *Br J Nutr* **100**, 1307-1314.
- [45] Hintze J (2008) PASS 2008. NCSS LLC, http://www. ncss.com
- [46] Cohen J (1988) Statistical Power Analysis for the Behavioral Sciences, Lawrence Erlbaum Associates, Hillsdale, New Jersey.
- [47] Morley JE (2010) Nutrition and the brain. *Clin Geriatr Med* **26**, 89-98.
- [48] Salerno-Kennedy R, Cashman KD (2007) The relationship between nutrient intake and cognitive performance in people at risk of dementia. *Ir J Med Sci* **176**, 193-198.
- [49] Mi W, van Wijk N, Cansev M, Sijben JW, Kamphuis PJ (2013) Nutritional approaches in the risk reduction and management of Alzheimer's disease. *Nutrition* 29, 1080-1089.
- [50] Min JY, Min KB (2014) Serum lycopene, lutein and zeaxanthin, and the risk of Alzheimer's disease mortality in older adults. *Dement Geriatr Cogn Disord* 37, 246-256.
- [51] Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P (2003) Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. *Neurobiol Aging* 24, 915-919.
- [52] Meagher KA, Thurnham DI, Beatty S, Howard AN, Connolly E, Cummins W, Nolan JM (2013) Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration. *Br J Nutr* **110**, 289-300.
- [53] Nolan JM, Akkali MC, Loughman J, Howard AN, Beatty S (2012) Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment. *Exp Eye Res* 101, 9-15.
- [54] Beatty S, Chakravarthy U, Nolan JM, Muldrew KA, Woodside JV, Denny F, Stevenson MR (2013) Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. *Ophthalmology* **120**, 600-606.

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902